NEW YORK, Jan. 19, 2016 /PRNewswire/ -- Wolf Popper LLP is investigating potential securities fraud claims on behalf of investors in Sarepta Therapeutics, Inc. securities (NASDAQ: SRPT) on the U.S. markets during the period May 20, 2015 through January 14, 2016. Sarepta investors can contact Fei-Lu Qian at 877.370.7703 or fqian@wolfpopper.com for more information.
On January 15, 2016, before the market opened, the U.S. Food and Drug Administration released briefing documents in advance of a January 22, 2016 Advisory Committee meeting to consider Sarepta's new drug application for etepliresen, a drug to treat Duchenne muscular dystrophy. The agency said that it had concerns about how Sarepta designed the trial for the drug, as well as the drug's efficacy and Sarepta's statistical analysis in the trial. Specifically, while the Company had represented in its public statements that it has a "comparable historical control group that we can show and really compare to," the briefing documents stated that the Company's "Study 201/202 is not a well-designed historically-controlled trial."
On the release of the briefing documents, Sarepta common stock declined $17.35 per share or nearly 55%, to close at $14.28 per share on January 15, 2016.
Wolf Popper LLP has extensive experience representing shareholders in securities class actions and has successfully recovered billions of dollars for defrauded investors. The reputation and expertise of the firm in representing shareholders has been repeatedly recognized by the courts, which have appointed the firm to major positions in securities litigation. See www.wolfpopper.com
Attorney Advertising: Prior Results Do Not Guarantee A Similar Outcome.
Wolf Popper LLP
Fei-Lu Qian
845 Third Avenue
New York, NY 10022
Tel.: 877.370.7703
Fax: 877.370.7704
Email: fqian@wolfpopper.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/wolf-popper-llp-announces-investigation-of-fraud-claims-on-behalf-of-investors-in-sarepta-therapeutics-inc-300205848.html
SOURCE Wolf Popper LLP
